NCT05256225 2026-03-19
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
23 trialsNCT04008797 2026-02-27
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT03603184 2025-05-09
AtTEnd
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT06942416 2025-04-24
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting
NCT01279291 2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT06363708 2024-04-12
Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer
Zhongnan Hospital
Phase NA Not yet recruiting
NCT03935256 2023-12-18
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
Phase 2 Unknown
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT01616303 2020-09-14
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
Phase 2 Completed
NCT01219777 2018-02-08
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00129727 2016-06-01
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Massachusetts General Hospital
Phase 2 Completed
NCT00002854 2015-08-26
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed
NCT02312804 2015-02-16
Ph Ib/BGJ398/Cervix and Other Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT00756847 2013-04-10
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
Sanofi
Phase 1 Completed
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed
NCT00750386 2011-05-23
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT01000896 2010-02-04
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
AstraZeneca
Phase 1 Withdrawn
NCT00001383 2008-03-04
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
National Institutes of Health Clinical Center (CC)
Phase 1 Completed